GALAPAGOS NV/S (NASDAQ:GLPG) was downgraded by equities research analysts at BidaskClub from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Wednesday, March 27th, BidAskClub reports.
Several other brokerages also recently weighed in on GLPG. Credit Suisse Group raised shares of GALAPAGOS NV/S from a “neutral” rating to an “outperform” rating in a report on Thursday, December 13th. Zacks Investment Research raised shares of GALAPAGOS NV/S from a “hold” rating to a “buy” rating and set a $115.00 target price on the stock in a report on Tuesday, December 11th. ValuEngine raised shares of GALAPAGOS NV/S from a “hold” rating to a “buy” rating in a report on Friday, March 1st. Svb Leerink began coverage on shares of GALAPAGOS NV/S in a report on Friday, February 22nd. They issued an “outperform” rating on the stock. Finally, Cowen reaffirmed a “buy” rating on shares of GALAPAGOS NV/S in a research note on Friday, February 22nd. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, eleven have given a buy rating and two have assigned a strong buy rating to the company’s stock. GALAPAGOS NV/S presently has an average rating of “Buy” and an average target price of $125.83.
NASDAQ:GLPG traded up $1.45 during trading hours on Wednesday, hitting $115.43. 165,448 shares of the stock traded hands, compared to its average volume of 201,716. GALAPAGOS NV/S has a 1 year low of $85.00 and a 1 year high of $125.48. The company has a market capitalization of $5.91 billion, a P/E ratio of -43.72 and a beta of 1.68.
GALAPAGOS NV/S Company Profile
Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients.
Featured Article: Certificate of Deposit (CD)
Receive News & Ratings for GALAPAGOS NV/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GALAPAGOS NV/S and related companies with MarketBeat.com's FREE daily email newsletter.